ArticleBMC plant biology2025
Metabolomics combined with network pharmacology reveals the anti-hepatoma effects of terpenoids from Polygonatum kingianum var. grandifolium and Polygonatum sibiricum Redouté as well as differences in their terpenoid metabolites.
Article in BMC plant biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver cancer remains a smajor cause of mortality worldwide, underscoring the urgent need for novel natural therapeutics. Polygonatum kingianum var. grandifolium (PK) and Polygonatum sibiricum Redouté (PS) are rice in terpenoids, yet their anti-liver cancer mechanisms remain poorly understood. This study used metabolism, network analysis, molecular docking, and molecular dynamics simulations to investigate their therapeutic potential. Metabolomic analysis identified nine differential terpenoid metabolites, with Maslinic acid and Alphitolic acid being species-specific. Network analysis revealed 23 liver cancer-related targets, including five key proteins: HMGCR, PTGS2, ESR1, PPARG, and PGR. Functional enrichment analysis identified 126 GO terms and 11 KEGG pathways (P < 0.05). Molecular docking suggested strong binding affinities between core compounds and targets, while molecular dynamics simulations confirmed the stability of maslinic acid and alphitolic acid with their respective targets. This study enhances the pharmacological understanding of Polygonatum species and offers promising insights for the development of novel liver cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.